Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen.

@article{Kamimura2013HigherIO,
  title={Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen.},
  author={Tomohiko Kamimura and Toshihiro Miyamoto and Noriko Yokota and Shuichiro Takashima and Yong Pill Chong and Yoshikiyo Ito and Koichi Akashi},
  journal={European journal of haematology},
  year={2013},
  volume={90 2},
  pages={157-61}
}
Subcutaneous (sc) rather than intravenous administration of bortezomib (Bor) is becoming more common for treating multiple myeloma (MM) because scBor results in lower incidence and severity of peripheral neuropathy and has equivalent efficacy. Bor is an irritant cytotoxic agent when it leaks out; therefore, it is recommended that injections of scBor should be rotated among eight different sites on the abdomen and thigh. However, detailed information about injection site reaction (ISR) has not… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses

Journal of the advanced practitioner in oncology • 2015
View 2 Excerpts
Highly Influenced

Association of skin necrosis with subcutaneous immunoglobulin therapy.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology • 2014

Similar Papers

Loading similar papers…